These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 8585542)
1. Will increases in chemotherapy dose intensity improve outcome of patients with common malignancies? Tannock I Am J Med; 1995 Dec; 99(6A):68S-69S. PubMed ID: 8585542 [No Abstract] [Full Text] [Related]
2. Will increases in dose intensity improve outcome: con. Souhami RL Am J Med; 1995 Dec; 99(6A):71S-76S. PubMed ID: 8585544 [No Abstract] [Full Text] [Related]
3. Dose: a critical factor in cancer chemotherapy. Frei E; Canellos GP Am J Med; 1980 Oct; 69(4):585-94. PubMed ID: 6999898 [No Abstract] [Full Text] [Related]
4. The importance of dose intensity in the outcome of chemotherapy. Hryniuk WM Important Adv Oncol; 1988; ():121-41. PubMed ID: 3042601 [No Abstract] [Full Text] [Related]
5. Will increases in dose intensity improve outcome: pro. Hryniuk W Am J Med; 1995 Dec; 99(6A):69S-70S. PubMed ID: 8585543 [No Abstract] [Full Text] [Related]
6. Can a rational design for metronomic chemotherapy dosing be devised? Maraveyas A; Lam T; Hetherington JW; Greenman J Br J Cancer; 2005 Apr; 92(8):1588-90. PubMed ID: 15846302 [No Abstract] [Full Text] [Related]
9. Relative dose intensity: improving cancer treatment and outcomes. Lenhart C Oncol Nurs Forum; 2005 Jul; 32(4):757-64. PubMed ID: 15990905 [TBL] [Abstract][Full Text] [Related]
10. How strong is the case for intensive cancer chemotherapy? Tattersall MH; Tobias JS Lancet; 1976 Nov; 2(7994):1071-2. PubMed ID: 62911 [No Abstract] [Full Text] [Related]
11. Drug dosage intensity--a panel discussion. McGuire WL; Goldie J; Hryniuk W; Tormey DC Breast Cancer Res Treat; 1987; 9(2):87-100. PubMed ID: 3620720 [TBL] [Abstract][Full Text] [Related]
13. [Perspectives of improvement of chemotherapy effectiveness in disseminated solid tumors]. Sivashinskiĭ MS Vopr Onkol; 2004; 50(2):237-42. PubMed ID: 15176230 [No Abstract] [Full Text] [Related]
14. Metronomic chemotherapy: teaching old drugs new tricks? Vogelzang N Clin Adv Hematol Oncol; 2004 Jul; 2(7):432-3. PubMed ID: 16163217 [No Abstract] [Full Text] [Related]
15. Multifractionated dosing for cancer chemotherapy: a novel schedule and a work in progress. Lokich J Cancer Invest; 1999; 17(7):551-4. PubMed ID: 10518201 [No Abstract] [Full Text] [Related]
16. Implications of dose intensity for cancer clinical trials. Semin Oncol; 1987 Dec; 14(4 Suppl 4):1-44. PubMed ID: 3686043 [No Abstract] [Full Text] [Related]
17. [Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations]. Hanauske AR Med Klin (Munich); 1996 Apr; 91 Suppl 3():68-70. PubMed ID: 8692122 [No Abstract] [Full Text] [Related]
18. Intraperitoneal chemotherapy in the management of malignant disease. Markman M Expert Rev Anticancer Ther; 2001 Jun; 1(1):142-8. PubMed ID: 12113122 [TBL] [Abstract][Full Text] [Related]
19. [Dose intensity in cancer chemotherapy (including high dose chemotherapy)]. Ariyoshi Y; Ogawa M Gan To Kagaku Ryoho; 1994 Dec; 21(16):2699-707. PubMed ID: 7993104 [TBL] [Abstract][Full Text] [Related]
20. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Seymour L; Bramwell V; Moran LA Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]